

PAPER

 View Article Online
 View Journal | View Issue
Cite this: *RSC Adv.*, 2019, 9, 18256

One-pot regioselective C–H activation iodination–cyanation of 2,4-diarylquinazolines using malononitrile as a cyano source†

 Ziqiao Yan,^a Banlai Ouyang,^b Xunchun Mao,^a Wei Gao,^a Zhihong Deng^a
 and Yiyuan Peng^{ib}*^a

Received 21st April 2019

Accepted 28th May 2019

DOI: 10.1039/c9ra02979f

rsc.li/rsc-advances


A one-pot cyanation of 2,4-arylquinazoline with NIS and malononitrile has been developed. The one-pot reaction includes two steps. The Rh-catalyzed selective C–H activation/iodization of 2,4-diarylquinazoline with NIS, and then Cu-catalyzed cyanation of the corresponding iodinated intermediate with malononitrile to selectively give 2-(2-cyanoaryl)-4-arylquinazolines or 2-(2,6-dicyanoaryl)-4-arylquinazolines in good to excellent yields.

Introduction

Aromatic nitriles have broad applications in agrochemicals, pharmaceuticals and materials science. The nitrile moiety also serves as a pivotal precursor for a multitude of conversions into a great number of other functional groups, such as hydrolysis into carboxyl or amide, reduction into aldehydes or amines, cycloaddition into heterocycles, *etc.*¹ Consequently, a number of methods have been developed to introduce a cyanogen group to an aromatic ring. Various catalytic systems and cyanating agents have been established. Of these transformations, transition-metal-catalyzed cyanation of aryl halides^{2a} or aromatic C–H bond activation/cyanation was an elegant route to aryl nitriles.^{2b} Cu(CN)₂,³ Zn(CN)₂,⁴ NaCN and KCN,⁵ CuSCN,⁶ cyanogen halides,⁷ TMSCN,⁸ NaN₃,⁹ and K₄[Fe(CN)₆]¹⁰ have been used as cyanation agents to introduce CN into organic molecules. Organic cyanide sources and their combined cyano-groups, such as CH₃NO₂,¹¹ acetone cyanohydrin,¹² *N*-cyano-*N*-phenyl-*p*-toluenesulfonamide (NCTS),¹³ aryl(cyano)iodonium triflates,¹⁴ amine/DMSO,¹⁵ DMF,¹⁶ formamide,^{16f,16g} ethyl cyanoacetate,¹⁷ ethyl(ethoxymethylene)cyanoacetate,¹⁸ benzyl cyanide,¹⁹ *tert*-butyl nitrite (TBN),²⁰ isocyanides,²¹ and acetonitrile²² have been used in cyanation for more solubility in organic solvents.

Recent, malononitrile, being more inexpensive, readily industry available, less toxic, stable and easy-to-handle, had been used as an alternative organic cyano-group source.²³

Although attempts have been made to utilize malononitrile as the cyano-group source in several aryl halogens cyanation reactions (Scheme 1a),²³ there is no report about utilizing it as



Scheme 1 Some previous works and this work.

^aKey Laboratory of Functional Small Organic Molecule, Ministry of Education, Jiangxi Province's Key Laboratory of Green Chemistry, Jiangxi Normal University, Nanchang, Jiangxi, 330022, China. E-mail: yypeng@jxnu.edu.cn

^bDepartment of Chemistry, Nanchang Normal University, Nanchang 330032, China

† Electronic supplementary information (ESI) available: Experimental procedure, characterization data, ¹H and ¹³C NMR spectra of compounds 3 and 4. See DOI: 10.1039/c9ra02979f



a cyano-group source in one-pot C–H bond activation/cyanation.

On the other hand, quinazoline core structure exhibits a wide range of important potential biological activities.^{24,25} For example, Erlotinib and Gefitinib are well-known lung cancer drugs.²⁶ Prazosin is used for curing high blood pressure²⁷ and Trimetrexate has been used in the treatment of pneumocystis pneumonia²⁸ (Fig. 1). Thus tremendous efforts have been devoted to develop new synthetic methods for the construction of diverse quinazoline architectures and evaluate their bioactivities.²⁹ In the past few years, our group has focused extensively on the development methods for the synthesis of quinazoline skeletons and the late-stage functionalization of the quinazoline core with a wish to construct a quinazoline-based molecular library for bioactivity assay.³⁰


However, the construction of quinazoline core coupling-nitrile moiety had been rarely reported. In 2013, we reported palladium catalyzed cyanation of quinazoline-4-tosylates with CuCN for access to quinazoline-4-nitriles (Scheme 1b).³¹ In 2017, we disclosed quinazoline-directed selective *ortho*-iodination of 2,4-diarylquinazolines for the synthesis of 2-(2-iodoaryl)-4-arylquinazolines (Scheme 1c).³² Very recently, iodination of 2,4-diarylquinazoline with NIS catalyzed by rhodium, and then trifluoromethylthiolation of the corresponding iodides for the synthesis of SCF₃-substituted 2,4-diarylquinazolines was reported in our group (Scheme 1d).³³ Based on these, we here reported selective synthesis of 2-(2-cyanophenyl)-4-phenylquinazolines and 2-(2,4-dicyanophenyl)-4-phenylquinazolines by one-pot C–H activation iodination/cyanation using malononitrile as a cyano-group source (Scheme 1e).

Results and discussion

Our interest in this particular on the regioselective C–H activation/cyanation of 2,4-diarylquinazolines originated from our recent studies that [RhCp*Cl₂]₂/AgSbF₆ catalyzed iodination of 2,4-arylquinazoline.³³ Here, we first optimize the reaction conditions of one-pot C–H iodination/cyanation of 2,4-phenylquinazoline. To avoid produce mixture of mono- and bis-functionalization products, 2-(*o*-methylphenyl)-4-(*p*-methylphenyl)quinazoline **1a**, which one of *ortho* position was blocked by a methyl, was chosen as the model substrate for the optimization of the one-pot cyanation conditions. According to our

previous work,³³ the standard iodination protocol was carried out by using **1a** (1.0 eq.), NIS (*N*-iodosuccinimide, 1.5 eq.), [RhCp*Cl₂]₂ (1.0 mol%) and AgSbF₆ (8.0 mol%) in DCE at 85 °C for 30 min. When the iodination reaction was finished, the DCE solvent was removed under reduced pressure, and the mixture of malononitrile (2.0 eq.), catalyst-system Cu₂O (10 mol%)–**L** (20 mol%), *t*-BuOK (2.0 eq.) and DMF (2.0 mL) as the solvent were added and then reacted at 120 °C. To our delight, the target product **3a** was isolated in a yield of 25% (Table 1, entry 1). Various of bases, such as K₂CO₃, KOH, Cs₂CO₃, and NaOH, were screened, and *t*-BuOK was found to be the best one (entries 1–5). Different copper salts were then examined, and Cu₂O was proved to be the best selected, which resulted in a yield of 58% (entries 6–12). The results of solvents tested indicated that trace amount of product was detected in H₂O or acetone (not listed in Table 1); low yield of 47% and 49% were obtained in DMAC or DMSO (entries 13 and 14). Additive KF found to be beneficial to the reaction, and gave a yield up to 63% (entry 15). Among the ligands used, **L**₄ (Bathocuproine) was found to be more facilitating to the reaction than the others (entries 16–18). Excitingly,

Table 1 Optimization of the reaction conditions^{a,b}



Entry	[Cu]	L	Base	Solvent	Yield ^c
1	Cu(OAc) ₂	L ₁	<i>t</i> -BuOK	DMF	25
2	Cu(OAc) ₂	L ₁	NaOH	DMF	16
3	Cu(OAc) ₂	L ₁	K ₂ CO ₃	DMF	21
4	Cu(OAc) ₂	L ₁	KOH	DMF	15
5	Cu(OAc) ₂	L ₁	Cs ₂ CO ₃	DMF	18
6	CuCl	L ₁	<i>t</i> -BuOK	DMF	32
7	CuCO ₃	L ₁	<i>t</i> -BuOK	DMF	24
8	Cu(TFA) ₂	L ₁	<i>t</i> -BuOK	DMF	26
9	CuBr	L ₁	<i>t</i> -BuOK	DMF	48
10	CuSO ₄	L ₁	<i>t</i> -BuOK	DMF	45
11	Cu ₂ O	L ₁	<i>t</i> -BuOK	DMF	58
12	CuI	L ₁	<i>t</i> -BuOK	DMF	44
13	Cu ₂ O	L ₁	<i>t</i> -BuOK	DMAC	47
14	Cu ₂ O	L ₁	<i>t</i> -BuOK	DMSO	49
15	Cu ₂ O	L ₁	<i>t</i> -BuOK–KF	DMF	63
16	Cu ₂ O	L ₂	<i>t</i> -BuOK–KF	DMF	33
17	Cu ₂ O	L ₃	<i>t</i> -BuOK–KF	DMF	57
18	Cu ₂ O	L ₄	<i>t</i> -BuOK–KF	DMF	69
19	Cu₂O	L ₄	<i>t</i>-BuOK–KF	DMF : H₂O = 2 : 1	84
20	Cu ₂ O	L ₄	<i>t</i> -BuOK–KF	DMF : H ₂ O = 2 : 0.8	71
21	Cu ₂ O	L ₄	<i>t</i> -BuOK–KF	DMF : H ₂ O = 2 : 0.6	75
22 ^d	Cu ₂ O	L ₄	<i>t</i> -BuOK–KF	DMF : H ₂ O = 2 : 0.6	Trace

^a Optimized conditions are denoted in bold. ^b Reaction conditions: **1a** (0.1 mmol), NIS (1.5 eq.), [RhCp*Cl₂]₂ (1.0 mol%)–AgSbF₆ (8 mol%), malononitrile (2.0 eq.), [Cu] (10 mol%)–ligand (20 mol%), base (2.0 eq.), in solvent (2.0 mL) at 120 °C. ^c Isolated yield. ^d NIS was replaced by NBS.




Fig. 1 The quinazoline core structure of drugs.



adding 50 v% of water in DMF can improve the yield to 84% (entries 19–21) and short the reaction time from 18 h to 3 h. Finally, when NBS (*N*-bromosuccinimide) was used as the reactant instead of NIS under the standard reaction conditions, only trace amount of the desired product was detected.

We then started to investigate the scope and the generality of this reaction under optimized conditions [NIS (1.5 eq.), [RhCp*Cl₂]₂ (1.0%), AgSbF₆ (8.0 mol%), malononitrile (2.0 eq.), Cu₂O (10 mol%), Bathocuproine (20 mol%), *t*-BuOK (2.0 eq.), KF (2.0 eq.) in the solvent of DMF : H₂O = 2 : 1, at 120 °C for 3.5 hours]. The results are listed in Table 2.


As shown in Table 2, a variety of 2-(*o*-canyophenyl)-4-arylquinazolines were generated under the standard experimental conditions. In general, the electron-donating R¹, R², R³

group substituent fascinated the reactions, and gave higher yields than that of electron-withdrawing ones. For examples, when R² is a methyl, and R¹ is *p*-methyl or *p*-methoxy, the corresponding products **3a** and **3b** were obtained in excellent of yields of 84% and 85%. The reaction of electron-withdrawing fluorinated substrate **1d** gave good yield of 59%. The substituent group at the *meta* or *ortho* position of 4-phenyl, due to the steric hindrance, finished the corresponding products **3e**, **3f** and **3g** in a yield of 63%, 48% and 67%, respectively. When R² is chloro, the reactions gave the corresponding products **3h–3j** in good yields 79–49%.

Subsequently, the effects of substituent on the phenyl moiety of quinazoline mother ring were then examined. Pleasingly, methoxy and chloro functionalities were all tolerated, providing the desired products **3k–3q** in good to excellent yields. **3r** was obtained in a low yield due to double electron-withdrawing substituent effect.


As we seen, when R² is H, the reaction may produce mono-cyanation and bis-cyanation selectivity. In our previous work, exclusively generate mono-iodination on the 2-aryl group was obtained catalyzed by PbCl₂-PPh₃, and then cyanation of the corresponding 2-(2-iodoaryl)quinazolines using conventional procedure^{4e} could selective giving 2-(2-mono-nitrile) quinazolines. Thus, here we focus our attention on selective to produce bis-cyanation quinazolines in one-pot reaction. The results are listed in Table 3.

Table 2 Substrate scope exploration^{a,b}



^a Reaction conditions: **1a** (0.2 mmol), NIS (1.5 eq.), [RhCp*Cl₂]₂ (1.0 mol%), AgSbF₆ (8.0 mol%), DEC 2.0 mL, malononitrile (2.0 eq.), Cu₂O (10 mol%), Bathocuproine (20 mol%), *t*-BuOK (2.0 eq.), KF (2.0 eq.), DMF : H₂O = 2 : 1 (3.0 mL). ^b Isolated yield.

Table 3 Substrate scope exploration^{a,b}



^a Reaction conditions: (0.2 mmol), NIS (3.0 eq.), [RhCp*Cl₂]₂ (2.0 mol%), AgSbF₆ (16 mol%), DEC (2.0 mL); malononitrile (4.0 eq.), Cu₂O (20 mol%), Bathocuproine (40 mol%), *t*-BuOK (4.0 eq.), KF (4.0 eq.), DMF : H₂O = 2 : 1 (3.0 mL). ^b Isolated yield.



When 2,4-di-(*p*-methyl)phenylquinazoline **1a** was selected as the model substrate, and the corresponding reagents were adding double of the standard protocol above, the corresponding bis-cyanation product **4a** was obtained in a yield of 65% (Table 3). The electron-donating R¹, R², R³ group substituent also fascinating the reactions, and gave higher yields (**4a**, **4b**, **4f** and **4i**) than that of electron-withdrawing ones (**4d**, **4e**, **4g** and **4h**). Interestingly, dicyano-compounds were obtained in reasonable yields (**4j** and **4k**) when *m*-substituted of 2,4-diarylquinazolines were used.

In order to further explore the substrate scope, 2-phenylpyridine was then investigated under the standard conditions, however, the corresponding product **4l** was obtained in 23% yield. This result again disclosed that the directing properties of diazine in quinazoline are distinctive from that of pyridine.

To demonstrate the potential synthetic utility of this transformation, a gram-scale reaction of 2-(*o*-methyl)phenyl-4-(*p*-methyl)phenylquinazoline (**1a**) was carried out. As shown in Scheme 2a, the cyanation product (**3a**) was isolated in an 71% yield.

To further understand the reaction mechanism, a controlled experiment was conducted. When 2-(2-iodo-6-methylphenyl)-4-(*p*-methyl)phenylquinazoline (**2a**) was used as the reactant under the standard reaction conditions in Scheme 2b, the cyanation product (**3a**) was isolated in an 92% yield.

In view of the above results, a plausible mechanism was disclosed in Scheme 3. The one-pot iodination/cyanation reaction include two catalytic cycles. In the first catalytic cycle I, the reaction of [Cp*RhCl₂]₂ and AgSbF₆ forms [Cp*Rh(SbF₆)₂]₂, which reacted with **1** through C–H activation to give five-membered rhodacycle **A**, and then was oxidation addition with NIS to provide the Rh(IV) intermediate **B**, followed reductive eliminated to give iodide intermediate product **2** along with the Rh(III) **C**, which was acidized to regenerate catalyst [Cp*Rh(SbF₆)₂]₂ and finish catalytic cycle I.

In the second catalytic cycle II, the ligand was incorporated with Cu^IX to form the catalyst LCuX, and then incorporate with malononitrile to provide the complex **D**, which was reacted with *t*-BuOK to give intermediate **E**, and then undergoes

transmetalation to generate the active species LCu^ICN. The LCu^ICN subjected to oxidative addition with **2** to form five-membered cyclic Cu(III) **G**, and followed reductive eliminated to give product **3**, and release the LCu^IX catalyst and finish the catalytic cycle.

In summary, we here have developed methods for one-pot process for selective the synthesis of 2-(2-cyano)aryl-4-arylquinazolines or 2-(2,6-dicyano)aryl-4-arylquinazolines. The one-pot reaction include two steps, the Rh-catalyzed selective C–H activation iodization of 2,4-diarylquinazoline with NIS, and then Cu-catalyzed cyanation of the corresponding iodide intermediate with malononitrile to give 2-(*o*-cyanoaryl)-4-arylquinazolines or 2-(2,6-dicyano)aryl-4-arylquinazolines in good to excellent yields.

Experimental section


Unless otherwise noted, commercial reagents were purchased from Aldrich, Alfa, or other commercial suppliers. All solvents were dried and distilled according to standard procedures before use. Reactions were conducted in standard techniques on vacuum line. Analytical thin-layer chromatography (TLC) was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Flash column chromatography was performed using silica gel (60 Å pore size, 32–63 μm, standard grade). Organic solutions were concentrated on rotary evaporators at ~20 torr (house vacuum) at 25–35 °C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million (ppm) from internal standard tetramethylsilane (TMS) on the δ scale.

General procedure for preparation of 2-(*o*-cyanoaryl)-4-arylquinazoline **3** (**3a** as an example)

A mixture of 2,4-phenylquinazolines **1a** (0.2 mmol), NIS (0.3 mmol, 1.5 eq.), [RhCp*Cl₂]₂ (1.0 mol%), AgSbF₆ (8.0 mol%) in DCE (2.0 mL) was stirred at 85 °C, until **1a** was completed consumed (detected by TLC). The solvent was removed under reduced pressure. A mixture of malononitrile (2.0 eq.), Cu₂O (10 mol%), Bathocuproin (20 mol%), *t*-BuOK (2.0 eq.), KF (2.0 eq.) and DMF and water (3.0 mL 2 : 1) was added and stirred at 120 °C for 3 h. After completion of the reaction as indicated by TLC, the mixture was cooled to room temperature. The solvent was evaporated, residue was diluted with EtOAc (10 mL), washed with H₂O (10 mL), dried by anhydrous Na₂SO₄. Evaporation of the solvent followed purification by column chromatograph over silica gel provided the corresponding product **3a**.


General procedure for preparation of 2-(*o*-dicyanoaryl)-4-arylquinazoline **4** (**4a** as an example)

A mixture of 2,4-phenylquinazolines **1a** (0.2 mmol), NIS (0.6 mmol, 3.0 eq.), [RhCp*Cl₂]₂ (2.0 mol%), AgSbF₆ (16 mol%) and in DCE (2.0 mL) was stirred at 85 °C for 0.5 h, until **1a** was completed consumed. The solvent was removed under reduced pressure. A mixture of malononitrile (4.0 eq.), Cu₂O (20 mol%), Bathocuproin (40 mol%), *t*-BuOK (4.0 eq.), KF (4.0 eq.) in DMF



Scheme 2 A gram-scale reaction and controlled experiment.





Scheme 3 A plausible reaction mechanism.

and water (3.0 mL 2 : 1) was stirred at 120 °C. After completion of the reaction as indicated by TLC, the mixture was cooled to room temperature. The solvent was evaporated, residue was diluted with EtOAc (10 mL), washed with H₂O (10 mL), dried by anhydrous Na₂SO₄. Evaporation of the solvent followed purification by column chromatograph over silica gel provided the corresponding product **4a**.

2-(2-Cyano-6-methylphenyl)-4-(p-tolyl)quinazoline (3a). Compound was obtained as a white solid: yield 84%; mp 109–112 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.4 Hz, 1H), 8.18 (d, *J* = 8.4 Hz, 1H), 7.97 (t, *J* = 7.6 Hz, 1H), 7.82 (d, *J* = 8.0 Hz, 2H), 7.73–7.63 (m, 2H), 7.56 (d, *J* = 8.0 Hz, 1H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.40 (d, *J* = 8.0 Hz, 2H), 2.48 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 168.9, 160.2, 151.4, 142.5, 140.5, 138.3, 135.1, 134.1, 131.2, 130.3, 129.5, 129.1, 128.9, 128.3, 127.4, 121.6, 118.6, 113.1, 21.5, 20.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₁₈N₃: 336.1495; found: 336.1501.

2-(2-Cyano-6-methylphenyl)-4-(4-methoxyphenyl)quinazoline (3b). Compound was obtained as a white solid: yield 85%; mp 146–148 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 8.8 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.89 (d, *J* = 7.2 Hz, 1H), 7.83 (d, *J* = 8.8 Hz, 2H), 7.63–7.57 (m, 2H), 7.47 (d, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.03 (d, *J* = 8.8 Hz, 2H), 3.83 (s, 3H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.3, 161.4, 160.1, 151.4, 142.5, 138.3, 135.1, 134.1, 132.0, 131.2, 129.5, 129.1, 128.9, 128.2, 127.3, 121.6, 118.7, 114.2, 113.1, 55.5, 20.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₁₈N₃O: 352.1444; found: 352.1450.

2-(2-Cyano-6-methylphenyl)-4-phenylquinazoline (3c). Compound was obtained as a colorless oil: yield 76%; ¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 8.4, 1.6 Hz, 1H), 8.20 (d, *J* = 8.4 Hz, 1H), 7.98 (ddd, *J* = 8.0, 6.8, 1.6 Hz, 1H), 7.93–7.91 (m, 2H), 7.71–7.61 (m, 2H), 7.6–7.55 (m, 4H), 7.44 (t, *J* = 8.0 Hz, 1H), 2.48 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.8, 160.2, 151.4, 138.3, 137.0, 135.1, 134.2, 131.2, 130.2, 130.1, 129.2, 128.9, 128.7, 128.4, 127.3, 121.6, 118.6, 113.2, 20.4.

HRMS (ESI): *m/z* [M + H]⁺ calcd. for C₂₂H₁₆N₃: 322.1339; found: 322.1342.

2-(2-Cyano-6-methylphenyl)-4-(4-fluorophenyl)quinazoline (3d). Compound was obtained as a white solid: yield 59%; mp 122–124 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 8.8 Hz, 2H), 8.01–7.93 (m, 3H), 7.73–7.68 (m, 2H), 7.57 (d, *J* = 8.0 Hz, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.32–7.27 (m, 2H), 2.49 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 164.1 (d, ¹*J* = 249.0 Hz), 160.1, 151.5, 142.2, 138.3, 135.2, 134.3, 133.1 (d, ⁴*J* = 3.0 Hz), 132.4 (d, ³*J* = 9.0 Hz), 131.2, 129.3, 129.0, 128.5, 126.9, 121.5, 118.6, 115.9 (d, ²*J* = 22.0 Hz), 113.2, 20.3. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₂H₁₅FN₃: 340.1245; found: 340.1250.

2-(2-Cyano-6-methylphenyl)-4-(3-methylphenyl)quinazoline (3e). Compound was obtained as a yellow oil: yield 63%; ¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, *J* = 8.4 Hz, 1H), 8.19 (d, *J* = 8.4 Hz, 1H), 7.97 (t, *J* = 7.6 Hz, 1H), 7.73 (s, 1H), 7.70–7.66 (m, 3H), 7.55 (d, *J* = 7.6 Hz, 1H), 7.49–7.37 (m, 3H), 2.48 (s, 3H), 2.47 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.1, 160.2, 151.4, 142.5, 138.6, 138.3, 136.9, 135.1, 134.2, 131.1, 131.0, 130.7, 129.1, 128.9, 128.5, 128.3, 127.4, 121.7, 118.6, 113.1, 21.6, 20.4. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₁₈N₃: 336.1495; found: 336.1501.

2-(2-Cyano-6-methylphenyl)-4-(2-methylphenyl)quinazoline (3f). Compound was obtained as a yellow oil: yield 48%; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 8.4 Hz, 1H), 7.98 (ddd, *J* = 8.4, 6.8, 1.6 Hz, 1H), 7.76 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.67–7.61 (m, 2H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.46–7.41 (m, 3H), 7.39–7.34 (m, 2H), 2.40 (s, 3H), 2.21 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 160.5, 150.8, 142.6, 138.0, 136.3, 136.2, 134.9, 134.5, 130.8, 130.6, 129.5, 129.3, 129.0, 128.9, 128.4, 127.3, 125.8, 122.6, 118.2, 113.0, 20.1, 20.0. HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₃H₁₈N₃: 336.1495; found: 336.1503.

2-(2-Cyano-6-methylphenyl)-4-(naphthalen-1-yl)quinazoline (3g). Compound was obtained as a white solid: yield 67%; mp 148–150 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, *J* = 8.4 Hz, 1H),



8.05 (d, $J = 8.0$ Hz, 1H), 8.01–7.96 (m, 2H), 7.7–7.69 (m, 2H), 7.67–7.63 (m, 3H), 7.58–7.51 (m, 3H), 7.45–7.40 (m, 2H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.8, 160.6, 151.0, 142.5, 138.1, 135.0, 134.7, 134.2, 133.7, 131.5, 130.9, 130.1, 129.1, 129.0, 128.5, 128.4, 128.1, 127.6, 127.0, 126.4, 125.8, 125.1, 123.3, 118.4, 113.0, 20.3. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{18}\text{N}_3$: 372.1495, found: 372.1501.

2-(2-Cyano-6-chlorophenyl)-4-(*p*-tolyl)quinazoline (3h). Compound was obtained as a white solid: yield 79%; mp 121–124 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, $J = 8.4$ Hz, 1H), 8.20 (d, $J = 8.4$ Hz, 1H), 7.98 (td, $J = 8.46, 1.2$ Hz, 1H), 7.81 (d, $J = 8.0$ Hz, 2H), 7.75 (ddd, $J = 8.0, 7.2, 0.8$ Hz, 2H), 7.69 (ddd, $J = 8.4, 7.2, 0.8$ Hz, 1H), 7.48 (t, $J = 8.0$ Hz, 1H), 7.40 (d, $J = 8.0$ Hz, 2H), 2.47 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.1, 158.3, 151.4, 141.9, 140.6, 134.6, 134.5, 134.2, 134.0, 131.7, 130.3, 129.9, 129.5, 129.2, 128.6, 127.4, 122.0, 117.0, 114.9, 21.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{21}\text{N}_2\text{O}$: 406.1106, found: 406.1102.

2-(2-Cyano-6-chlorophenyl)-4-(3-methylphenyl)quinazoline (3i). Compound was obtained as a yellow oil: yield 59%; ^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 8.4, 0.4$ Hz, 1H), 8.21 (d, $J = 8.4$ Hz, 1H), 7.99 (ddd, $J = 8.4, 7.6, 1.6$ Hz, 1H), 7.78–7.66 (m, 5H), 7.50 (d, $J = 7.6$ Hz, 1H), 7.47 (d, $J = 7.2$ Hz, 1H), 7.39 (d, $J = 7.6$ Hz, 1H), 2.48 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 158.3, 151.3, 141.9, 138.7, 136.7, 134.6, 134.5, 134.3, 131.7, 131.1, 130.7, 130.0, 129.2, 128.7, 128.6, 127.5, 127.4, 122.0, 117.0, 114.9, 21.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{15}\text{ClN}_3$: 356.0949, found: 356.0955.

2-(2-Cyano-6-chlorophenyl)-4-(2-methylphenyl)quinazoline (3j). Compound was obtained as a yellow solid: yield 49%; mp 101–103 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.23 (d, $J = 8.4$ Hz, 1H), 8.00 (ddd, $J = 8.4, 6.8, 1.6$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.74 (dt, $J = 8.0, 1.6$ Hz, 2H), 7.66 (ddd, $J = 8.4, 6.8, 1.2$ Hz, 1H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.46–7.34 (m, 4H), 2.23 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.9, 158.5, 150.9, 142.0, 136.4, 136.0, 134.7, 134.5, 134.3, 131.5, 130.7, 130.1, 129.6, 129.4, 129.1, 128.8, 127.3, 125.8, 123.0, 116.8, 114.7, 20.0. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{15}\text{ClN}_3$: 356.0949, found: 356.0951.

2-(2-Cyano-6-methylphenyl)-4-(*p*-tolyl)-6-methoxyl quinazoline (3k). Compound was obtained as a colorless oil: yield 88%; ^1H NMR (400 MHz, CDCl_3) δ 8.08 (d, $J = 8.8$ Hz, 1H), 7.82 (d, $J = 8.0$ Hz, 2H), 7.66 (d, $J = 7.2$ Hz, 1H), 7.61 (dd, $J = 9.2, 2.8$ Hz, 1H), 7.54 (d, $J = 7.6$ Hz, 1H), 7.50 (d, $J = 2.8$ Hz, 1H), 7.43–7.38 (m, 3H), 3.89 (s, 3H), 2.48 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.0, 159.0, 158.3, 147.6, 142.6, 140.2, 138.3, 135.0, 134.5, 131.1, 130.6, 129.9, 129.5, 128.7, 126.8, 122.6, 113.2, 104.5, 55.8, 21.5, 20.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}$: 366.1601, found: 366.1606.

2-(2-Cyano-6-methylphenyl)-4-(3-methylphenyl)-6-methoxylquinazoline (3l). Compound was obtained as a colorless oil: yield 75%; ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, $J = 9.2$ Hz, 1H), 7.74 (s, 1H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.66 (d, $J = 8.4$ Hz, 1H), 7.62 (dd, $J = 9.2, 2.8$ Hz, 1H), 7.54 (d, $J = 7.6$ Hz, 1H), 7.49–7.37 (m, 4H), 3.88 (s, 3H), 2.48 (s, 3H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.2, 159.0, 158.3, 147.6, 142.6, 138.7, 138.3, 137.3, 135.0, 131.1, 130.8, 130.6, 130.5, 128.7, 128.5, 126.93, 126.9, 122.6, 118.6, 113.2, 104.5, 55.8, 21.6, 20.3. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}$: 366.1601, found: 366.1606.

2-(2-Cyano-6-methylphenyl)-4-(*p*-tolyl)-6-chloro-quinazoline (3m). Compound was obtained as a yellow solid: yield 55%; mp 106–108 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.22 (d, $J = 2.0$ Hz, 1H), 8.13 (d, $J = 8.8$ Hz, 1H), 7.90 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.80 (d, $J = 8.0$ Hz, 2H), 7.68 (d, $J = 7.6$ Hz, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.46–7.41 (m, 3H), 2.48 (s, 3H), 2.47 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.0, 160.4, 149.9, 142.0, 140.9, 138.3, 135.1, 135.1, 134.1, 133.6, 131.2, 130.8, 130.2, 129.7, 129.0, 126.1, 122.2, 118.5, 113.2, 21.5, 20.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_3$: 370.1106, found: 370.1111.

2-(2-Cyano-6-methylphenyl)-4-(3-methylphenyl)-6-chloro-quinazoline (3n). Compound was obtained as a yellow oil: yield 54%; ^1H NMR (400 MHz, CDCl_3) δ 8.20 (d, $J = 2.0$ Hz, 1H), 8.13 (d, $J = 9.2$ Hz, 1H), 7.90 (dd, $J = 9.6, 2.0$ Hz, 1H), 7.70–7.64 (m, 3H), 7.55 (d, $J = 7.6$ Hz, 1H), 7.51–7.40 (m, 3H), 2.49 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.3, 160.4, 149.9, 142.1, 138.9, 138.3, 136.4, 135.2, 135.1, 134.1, 131.3, 131.2, 130.8, 130.6, 129.1, 128.7, 127.3, 126.1, 122.2, 118.5, 113.2, 21.6, 20.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_3$: 370.1106, found: 370.1111.

2-(2-Cyano-6-methylphenyl)-4-(2-methylphenyl)-6-chloro-quinazoline (3o). Compound was obtained as a yellow oil: yield 63%; ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, $J = 9.2$ Hz, 1H), 7.90 (dd, $J = 9.2, 2.4$ Hz, 1H), 7.72 (d, $J = 2.0$ Hz, 1H), 7.65 (d, $J = 7.6$ Hz, 1H), 7.54 (d, $J = 7.6$ Hz, 1H), 7.48–7.38 (m, 5H), 2.39 (s, 3H), 2.22 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.9, 160.7, 149.4, 142.2, 138.0, 136.2, 135.6, 135.5, 135.0, 134.3, 130.9, 130.9, 130.8, 129.8, 129.3, 129.1, 126.0, 125.9, 123.2, 118.2, 113.0, 20.2, 20.1. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_3$: 370.1106, found: 370.1113.

2-(2-Cyano-6-methylphenyl)-4-(naphthalen-1-yl)-6-chloro-quinazoline (3p). Compound was obtained as a yellow oil: yield 89%; ^1H NMR (400 MHz, CDCl_3) δ 8.20 (d, $J = 8.8$ Hz, 1H), 8.07 (dd, $J = 7.2, 1.6$ Hz, 1H), 7.98 (d, $J = 8.0$ Hz, 1H), 7.92 (dd, $J = 8.8, 2.0$ Hz, 1H), 7.72 (d, $J = 2.4$ Hz, 1H), 7.72–7.63 (m, 3H), 7.62 (s, 1H), 7.57–7.53 (m, 2H), 7.48–7.41 (m, 2H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.04, 160.8, 149.6, 142.1, 138.1, 135.7, 135.0, 134.30, 133.8, 133.5, 131.4, 131.0, 130.80, 130.4, 129.1, 128.5, 128.1, 127.2, 126.6, 126.2, 125.5, 125.1, 123.9, 118.3, 113.0, 20.3. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{17}\text{ClN}_3$: 406.1106, found: 406.1102.

2-(2-Cyano-6-chlorophenyl)-4-(2-methylphenyl)-6-methoxyl quinazoline (3q). Compound was obtained as a yellow oil: yield 72%; ^1H NMR (400 MHz, CDCl_3) δ 8.12 (d, $J = 9.2$ Hz, 1H), 7.72 (ddd, $J = 9.2, 8.0, 1.2$ Hz, 2H), 7.63 (dd, $J = 9.6, 2.8$ Hz, 1H), 7.49–7.34 (m, 5H), 6.96 (d, $J = 2.8$ Hz, 1H), 3.80 (s, 3H), 2.24 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.8, 159.3, 156.4, 147.1, 142.1, 136.3, 136.3, 134.6, 134.3, 131.4, 130.8, 130.6, 129.9, 129.5, 129.2, 127.5, 125.9, 124.0, 116.9, 114.8, 104.2, 55.8, 20.0. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_3\text{O}$: 386.1055, found: 386.1057.

2-(2-Cyano-6-methylphenyl)-4-(4-fluorophenyl)-6-chloro-2-quinazoline (3r). Compound was obtained as a yellow solid: yield 29%; mp: 126–128 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (d, $J = 2.0$ Hz, 1H), 8.15 (d, $J = 8.8$ Hz, 1H), 7.95–7.91 (m, 3H), 7.69 (d, $J = 7.2$ Hz, 1H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.46 (t, $J = 8.0$ Hz,



1H), 7.34–7.29 (m, 2H), 2.48 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 164.4 (d, $^1J = 238.0$ Hz), 163.0, 150.0, 141.8, 138.3, 135.3 (d, $^3J = 11.0$ Hz) 134.4, 132.5 ($^4J = 3.0$ Hz), 123.4, 132.3, 131.3, 131.0, 129.2, 125.7, 122.0, 118.6, 116.2 (d, $^2J = 21.0$ Hz), 113.2, 20.4. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{14}\text{ClFN}_3$: 374.0855, found: 374.0860.

2-(2,6-Dicyano-4-methylphenyl)-4-(*p*-tolyl)quinazoline (4a). Compound was obtained as a white solid: yield 65%; mp 158–160 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (dd, $J = 8.4, 1.2$ Hz, 1H), 8.26 (dd, $J = 8.4, 1.2$ Hz, 1H), 8.00 (ddd, $J = 8.4, 6.8, 1.2$ Hz, 1H), 7.93 (d, $J = 8.0$ Hz, 2H), 7.70 (s, 2H), 7.71 (ddd, $J = 8.4, 6.8, 1.2$ Hz, 1H), 7.42 (d, $J = 8.0$ Hz, 2H), 2.53 (s, 3H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.2, 156.3, 151.4, 142.4, 140.8, 140.6, 138.3, 134.4, 133.9, 130.5, 129.5, 129.3, 128.9, 127.4, 122.0, 117.3, 114.5, 21.5, 20.8. HRMS calcd. For $\text{C}_{24}\text{H}_{17}\text{N}_4$: 361.1448, found: 361.1452.

2-(2,6-Dicyano-4-methoxyphenyl)-4-(*p*-tolyl)quinazoline (4b). Compound was obtained as a white solid: yield 72%; mp 194–196 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (dd, $J = 8.8, 1.2$ Hz, 1H), 8.25 (d, $J = 9.2, 1.2$ Hz, 1H), 7.98 (ddd, $J = 8.4, 6.8, 1.2$ Hz, 1H), 7.92 (d, $J = 8.0$ Hz, 2H), 7.70 (ddd, $J = 8.4, 7.6, 1.2$ Hz, 1H), 7.55 (s, 2H), 7.42 (d, $J = 8.0$ Hz, 2H), 3.96 (s, 3H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.1, 159.7, 156.1, 151.5, 140.8, 137.3, 134.3, 134.0, 130.5, 129.5, 129.3, 128.7, 127.4, 123.4, 122.0, 117.1, 115.7, 56.4, 21.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{17}\text{N}_4\text{O}$: 377.1397, found: 377.1402.

2-(2,6-Dicyanophenyl)-4-(*p*-tolyl)quinazoline (4c). Compound was obtained as a colorless oil: yield 53%; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.4$ Hz, 1H), 8.27 (d, $J = 8.4$ Hz, 1H), 8.07 (d, $J = 7.6$ Hz, 2H), 8.01 (t, $J = 8.0$ Hz, 1H), 7.93 (d, $J = 8.0$ Hz, 2H), 7.76–7.67 (m, 2H), 7.43 (d, $J = 8.0$ Hz, 2H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 156.2, 151.4, 145.2, 140.9, 137.7, 134.6, 133.9, 130.5, 129.7, 129.6, 129.4, 129.1, 127.5, 122.1, 117.1, 114.7, 21.6. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{15}\text{N}_4$: 347.1291, found: 347.1294.

2-(2,6-Dicyano-4-chlorophenyl)-4-(*p*-tolyl)quinazoline (4d). Compound was obtained as a yellow solid: yield 47%; mp: 172–175 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.0$ Hz, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 8.04–8.00 (m, 3H), 7.92 (d, $J = 8.4$ Hz, 2H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.43 (d, $J = 7.6$ Hz, 2H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 155.4, 151.4, 143.3, 141.0, 137.5, 136.0, 134.6, 133.7, 130.5, 129.6, 129.4, 129.2, 127.5, 122.1, 116.1, 116.0, 21.6. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{14}\text{ClN}_4$: 381.0902, found: 381.0907.

2-(2,6-Dicyano-4-fluorophenyl)-4-(*p*-tolyl)quinazoline (4e). Compound was obtained as a yellow solid: yield 62%; mp: 170–173 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (dd, $J = 8.4, 0.4$ Hz, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 8.01 (ddd, $J = 8.4, 7.2, 1.2$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.78 (d, $J = 7.6$ Hz, 2H), 7.73 (ddd, $J = 8.4, 7.2, 1.2$ Hz, 1H), 7.42 (d, $J = 8.0$ Hz, 2H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 161.4 (d, $^1J = 254.0$ Hz), 155.4, 151.4, 141.7 (d, $^3J = 4.0$ Hz), 141.0, 134.6, 133.8, 130.5, 129.5, 129.3, 129.1, 127.5, 125.1 (d, $^2J = 24.0$ Hz), 122.1, 116.5 (d, $^3J = 10.0$ Hz), 116.0 (d, $^4J = 2.0$ Hz), 21.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{14}\text{FN}_4$: 365.1197, found: 365.1121.

2-(2,6-Dicyano-4-methylphenyl)-4-(4-methoxyphenyl)quinazoline (4f). Compound was obtained as a white solid: yield 72%; mp 149–

153 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.4$ Hz, 1H), 8.25 (d, $J = 8.4$ Hz, 1H), 8.03 (d, $J = 8.8$ Hz, 2H), 7.98 (ddd, $J = 8.4, 6.8, 1.2$ Hz, 1H), 7.86 (s, 2H), 7.71 (ddd, $J = 8.4, 6.8, 1.2$ Hz, 1H), 7.14 (d, $J = 8.8$ Hz, 2H), 3.92 (s, 3H), 2.53 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.6, 161.7, 156.2, 151.5, 142.5, 140.6, 138.3, 134.3, 132.3, 129.4, 129.3, 128.8, 127.4, 122.0, 117.3, 114.5, 114.3, 55.5, 20.8; HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{17}\text{N}_4\text{O}$: 377.1397, found: 377.1404.

2-(2,6-Dicyano-4-methylphenyl)-4-(4-chlorophenyl)quinazoline (4g). Compound was obtained as a yellow solid: yield 65%; mp: 187–190 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (d, $J = 8.4$ Hz, 1H), 8.22 (d, $J = 8.0$ Hz, 1H), 8.01 (ddd, $J = 8.0, 6.8, 1.2$ Hz, 1H), 7.97 (d, $J = 8.4$ Hz, 2H), 7.87 (s, 2H), 7.73 (ddd, $J = 8.0, 6.8, 1.2$ Hz, 1H), 7.60 (d, $J = 8.4$ Hz, 2H), 2.53 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.8, 156.2, 151.5, 142.1, 140.8, 138.3, 136.9, 135.1, 134.6, 131.9, 129.6, 129.2, 129.1, 126.8, 121.8, 117.2, 114.5, 20.8. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{14}\text{ClN}_4$: 381.0902, found: 381.0907.

2-(2,6-Dicyano-4-methylphenyl)-4-(4-fluorophenyl)quinazoline (4h). Compound was obtained as a yellow solid: yield 54%; mp 209–212 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (d, $J = 8.4$ Hz, 1H), 8.24 (d, $J = 8.4$ Hz, 1H), 8.06–8.0 (m, 3H), 7.87 (s, 2H), 7.74 (ddd, $J = 8.0, 7.6, 1.2$ Hz, 1H), 7.31 (t, $J = 8.4$ Hz, 2H), 2.53 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.7 (d, $^1J = 243.0$ Hz), 156.2, 151.5, 142.2, 140.8, 138.3, 134.6, 132.8 (d, $^4J = 3.0$ Hz), 132.7 (d, $^3J = 9.0$ Hz), 129.5, 129.1, 127.0, 121.9, 117.2, 116.1, 116.0 (d, $^2J = 22.0$ Hz), 114.5, 20.8; HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{14}\text{FN}_4$: 365.1197, found: 365.1121.

2-(2,6-Dicyano-4-methylphenyl)-4-(*p*-tolyl)-6-methoxyquinazoline (4i). Compound was obtained as a white solid: yield 68%; mp 156–159 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.16 (d, $J = 9.2$ Hz, 1H), 7.93 (d, $J = 8.0$ Hz, 2H), 7.84 (s, 2H), 7.63 (dd, $J = 9.2, 2.8$ Hz, 1H), 7.54 (d, $J = 2.8$ Hz, 1H), 7.42 (d, $J = 8.0$ Hz, 2H), 3.90 (s, 3H), 2.51 (s, 3H), 2.48 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.2, 159.5, 154.4, 147.6, 142.6, 140.5, 140.2, 138.2, 134.3, 130.8, 130.1, 129.5, 127.1, 123.1, 117.3, 114.4, 104.6, 55.8, 21.5, 20.7. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{N}_4\text{O}$: 391.1553, found: 391.1558.

2-(2,6-Dicyano-3-methylphenyl)-4-(*p*-tolyl)quinazoline (4j). Compound was obtained as a white solid: yield 68%; mp 128–130 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.34 (s, 1H), 8.22 (dd, $J = 8.4, 3.6$ Hz, 2H), 7.94–7.89 (m, 3H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.62 (t, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 8.0$ Hz, 2H), 7.35 (d, $J = 7.6$ Hz, 1H), 2.51 (s, 3H), 2.48 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.8, 158.5, 151.7, 143.4, 141.3, 140.6, 134.9, 134.3, 134.0, 131.3, 130.7, 130.6, 129.4, 129.2, 128.0, 127.3, 121.8, 119.7, 109.4, 21.9, 21.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{17}\text{N}_4$: 361.1448, found: 361.1452.

2-(2,6-Dicyano-3-chlorophenyl)-4-(*p*-tolyl)quinazoline (4k). Compound was obtained as a yellow solid: yield 37%; mp: 157–160 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.4$ Hz, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 8.02 (ddd, $J = 8.4, 7.2, 1.2$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.77–7.73 (m, 2H), 7.43 (d, $J = 7.6$ Hz, 2H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 155.8, 151.4, 147.5, 142.9, 141.0, 137.5, 134.6, 133.7, 130.6, 130.5, 129.5, 129.4, 129.3, 127.5, 122.3, 116.3, 115.6, 113.9, 112.9, 21.5. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{14}\text{ClN}_4$: 381.0902, found: 381.0907.

2-(2,6-Dicyanophenyl)pyridine (4l). Compound was obtained as a white solid: yield 23%; mp 140–142 °C; ^1H NMR (400 MHz,



CDCl_3) δ 8.78 (d, J = 4.8 Hz, 1H), 7.86–7.78 (m, 3H), 7.72–7.68 (m, 1H), 7.51 (td, J = 7.6, 1.2 Hz, 1H), 7.37 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.3, 150.0, 143.5, 134.1, 132.8, 131.0, 130.0, 128.7, 123.3, 123.2. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_9\text{N}_2$: 181.0760, found: 181.0769.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from National Natural Science Foundation of China (no. 21762020), Jiangxi Provincial Department of Science and Technology (no. 20171BAB203006), and key laboratory of Functional Small Organic Molecule, Ministry of Education, Jiangxi Normal University (no. KLFS-KF-201702) is gratefully acknowledged.

Notes and references

- (a) A. J. Fatiadi in *Preparation and Synthetic Applications of Cyano Compounds*, ed. S. Patai and Z. Rappoport, Wiley, New York, 1983, vol. 2, pp. 1057–1303; (b) Z. Rappoport, *The Chemistry of the Cyano Group*, Interscience, New York, 1970; (c) R. C. Larock, *Comprehensive Organic Transformations*, VCH, New York, 1989; (d) J. X. Qiao, X. Cheng, D. P. Modi, K. A. Rossi, J. M. Luetgen, R. M. Knabb, P. K. Jadhav and R. R. Wexler, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 29–35; (e) M. Tobisu and N. Chatani, *Chem. Soc. Rev.*, 2008, **37**, 300–307.
- (a) P. Anbarasan, T. Schareina and M. Beller, *Chem. Soc. Rev.*, 2011, **40**, 5049–5067; (b) Y. Y. Ping, Q. P. Ding and Y. Y. Peng, *ACS Catal.*, 2016, **6**, 5989–6005. For recent review, see: .
- G. P. Ellis and T. M. Romney-Alexander, *Chem. Rev.*, 1987, **87**, 779–797.
- (a) P. E. Maligres, M. S. Waters, F. Fleitz and D. Askin, *Tetrahedron Lett.*, 1999, **40**, 8193–8195; (b) R. Chidambaram, *Tetrahedron Lett.*, 2004, **45**, 1441–1444; (c) R. S. Jensen, A. S. Gajare, K. Toyota, M. Yoshifuji and F. Ozawa, *Tetrahedron Lett.*, 2005, **46**, 8645–8647; (d) A. Littke, M. Soumeillant, R. F. Kaltenbach, R. J. Cherney, C. M. Tarby and S. Kiau, *Org. Lett.*, 2007, **9**, 1711–1714.
- (a) K. Takagi, T. Okamoto, Y. Sakakibara and S. Oka, *Chem. Lett.*, 1973, 471–474; (b) B. A. Anderson, E. C. Bell, F. O. Ginah, N. K. Harn, L. M. Pagh and J. P. Wepsiec, *J. Org. Chem.*, 1998, **63**, 8224–8228; (c) M. Sundermeier, A. Zapf, M. Beller and J. Sans, *Tetrahedron Lett.*, 2001, **42**, 6707–6710; (d) A. Zanon, J. Klapars and S. L. Buchwald, *J. Am. Chem. Soc.*, 2003, **125**, 2890–2891; (e) R. K. Arvela and N. E. Leadbeater, *J. Org. Chem.*, 2003, **68**, 9122–9125; (f) A. V. Ushkov and V. V. Grushin, *J. Am. Chem. Soc.*, 2011, **133**, 10999–11005.
- G. Y. Zhang, J. T. Yu, M. L. Hu and J. Cheng, *J. Org. Chem.*, 2013, **78**, 2710–2714.
- (a) P. H. Gore, F. S. Kamounah and A. Y. Miri, *Tetrahedron*, 1979, **35**, 2927–2929; (b) M. Murai, R. Hatano, S. Kitabata and K. Ohe, *Chem. Commun.*, 2011, 2375–2377; (c) K. Okamoto, M. Watanabe, M. Murai, R. Hatano and K. Ohe, *Chem. Commun.*, 2012, 3127–3129.
- (a) N. Chatani and T. Hanafusa, *J. Org. Chem.*, 1986, **51**, 4714–4716; (b) M. Sundermeier, S. Mutyala, A. Zapf, A. Spannenberg and M. Beller, *J. Organomet. Chem.*, 2003, **684**, 50–55.
- (a) W. Zhou, L. Zhang and N. Jiao, *Angew. Chem., Int. Ed.*, 2009, **48**, 7094–7097; (b) W. Zhou, J. Xu, L. Zhang and N. Jiao, *Org. Lett.*, 2010, **12**, 2888–2891.
- (a) T. Schareina, A. Zapf and M. Beller, *Chem. Commun.*, 2004, 1388–1389; (b) T. Schareina, A. Zapf, W. Mägerlein, N. Müller and M. Beller, *Tetrahedron Lett.*, 2007, **48**, 1087–1090; (c) Y. Ren, W. Wang, S. Zhao, X. Tian, J. Wang, W. Yin and L. Cheng, *Tetrahedron Lett.*, 2009, **50**, 4595–4597; (d) C. DeBlase and N. E. Leadbeater, *Tetrahedron*, 2010, **66**, 1098–1101; (e) L. Liu, J. Li, J. Xu and J. T. Sun, *Tetrahedron Lett.*, 2012, **53**, 6954–6956; (f) T. Chatterjee, R. Dey and B. C. Ranu, *J. Org. Chem.*, 2014, **79**, 5875–5879.
- X. Chen, X. S. Hao, C. E. Goodhue and J. Q. Yu, *J. Am. Chem. Soc.*, 2006, **128**, 6790–6791.
- (a) M. Sundermeier, A. Zapf and M. Beller, *Angew. Chem., Int. Ed.*, 2003, **42**, 1661–1664; (b) M. Sundermeier, A. Zapf, S. Mutyala, W. Baumann, J. Sans, S. Weiss and M. Beller, *Chem.–Eur. J.*, 2003, **9**, 1828–1836; (c) H. J. Cristau, A. Ouali, J. F. Spindler and M. Taillefer, *Chem.–Eur. J.*, 2005, **11**, 2483–2492; (d) T. Schareina, A. Zapf, A. Cotté, M. Gotta and M. Beller, *Adv. Synth. Catal.*, 2011, **353**, 777–780.
- (a) J. Cui, J. Song, Q. Liu, H. Liu and Y. H. Dong, *Chem.–Asian J.*, 2018, **13**, 482–495 and references therein; (b) Y. Yang, Y. Zhang and J. Wang, *Org. Lett.*, 2011, **13**, 5608–5611; (c) P. Anbarasan, H. Neumann and M. Beller, *Angew. Chem., Int. Ed.*, 2011, **50**, 519–522.
- (a) T. Dohi, K. Morimoto, Y. Kiyono, H. Tohma and Y. Kita, *Org. Lett.*, 2005, **7**, 537–540; (b) Z. Shu, W. Ji, X. Wang, Y. Zhou, Y. Zhang and J. Wang, *Angew. Chem., Int. Ed.*, 2014, **53**, 2186–2189.
- (a) X. Ren, J. Chen, F. Chen and J. Cheng, *Chem. Commun.*, 2011, 6725–6727; (b) K. Zheng, B. Liu, S. Chen and F. Chen, *Tetrahedron Lett.*, 2013, **54**, 5250–5252.
- (a) J. Kim and S. Chang, *J. Am. Chem. Soc.*, 2010, **132**, 10272–10274; (b) G. Zhang, X. Ren, J. Chen, M. Hu and J. Cheng, *Org. Lett.*, 2011, **13**, 5004–5007; (c) J. Kim, J. Choi, K. Shin and S. Chang, *J. Am. Chem. Soc.*, 2012, **134**, 2528–2531; (d) A. B. Pawara and S. Chang, *Chem. Commun.*, 2014, 448–450; (e) S. Ding and N. Jiao, *J. Am. Chem. Soc.*, 2011, **133**, 12374–12377; (f) D. N. Sawant, Y. S. Wagh, P. J. Tambade, K. D. Bhatte and B. M. Bhanage, *Adv. Synth. Catal.*, 2011, **353**, 781–787; (g) A. B. Khemnar, D. N. Sawant and B. M. Bhanage, *Tetrahedron Lett.*, 2013, **54**, 2682–2684.
- (a) X. J. Wang and S. L. Zhang, *New J. Chem.*, 2017, **41**, 14826–14830; (b) S. Zheng, C. Yu and Z. Shen, *Org. Lett.*, 2012, **14**, 3644–3647.
- Z. L. Li, K. K. Sun and C. Cai, *Org. Chem. Front.*, 2018, **5**, 1848–1853.



- 19 (a) Q. Wen, J. Jin, Y. Mei, P. Lu and Y. Wang, *Eur. J. Org. Chem.*, 2013, 4032–4036; (b) Q. Wen, J. Jin, B. Hu, P. Lu and Y. Wang, *RSC Adv.*, 2012, 2, 6167–6169; (c) J. Jin, Q. Wen, P. Lu and Y. Wang, *Chem. Commun.*, 2012, 9933–9935.
- 20 (a) B. Lücke, K. V. Narayana, A. Martin and K. Jähnisch, *Adv. Synth. Catal.*, 2004, 346, 1407–1424; (b) Z. Shu, Y. Ye, Y. Deng, Y. Zhang and J. Wang, *Angew. Chem., Int. Ed.*, 2013, 52, 10573–10576; (c) D. Tsuchiya, Y. Kawagoe, K. Moriyama and H. Togo, *Org. Lett.*, 2013, 15, 4194–4197.
- 21 X. Jiang, J.-M. Wang, Y. Zhang, Z. Chen, Y.-M. Zhu and S.-J. Ji, *Tetrahedron*, 2015, 71, 4883–4887.
- 22 (a) M. D. Zhao, W. Zhang and Z. M. Shen, *J. Org. Chem.*, 2015, 80, 8868–8873 and references therein.; (b) Y. M. Zhu, L. Y. Li and Z. M. Shen, *Chem.–Eur. J.*, 2015, 21, 13246–13252.
- 23 (a) G. P. Lu, M. J. Bu and C. Cai, *Synlett*, 2014, 25, 547–550; (b) Z. Q. Jiang, Q. Huang, S. Chen, L. S. Long and X. G. Zhou, *Adv. Synth. Catal.*, 2012, 354, 589–592.
- 24 For recent review, see: X. F. Shang, S. L. Morris-Natschke, Y. Q. Liu, X. Guo, X. S. Xu, M. Goto and J. C. Li, *Med. Res. Rev.*, 2017, 1–54.
- 25 For selected examples, see: (a) S. G. Li, K. B. Wang, C. Gong, Y. Bao, N. B. Qin, D. H. Li and Z. L. Li, *Bioorg. Med. Chem. Lett.*, 2018, 28, 103–106; (b) Z. Haghighijoo, Q. Firuzi, B. Hemmateenejad, S. Emami, N. Edraki and R. Miri, *Bioorg. Chem.*, 2017, 74, 126–133; (c) L. J. Wilso, *Org. Lett.*, 2001, 3, 585–588; (d) W. Szczepankiewicz, P. Wagner, M. Danicki and J. Suwiński, *Tetrahedron Lett.*, 2003, 44, 2015–2017; (e) D. S. Yoon, Y. Han, T. M. Stark, J. C. Haber, B. T. Gregg and S. B. Stankovich, *Org. Lett.*, 2004, 6, 4775–4778; (f) Y. Z. Yan, Y. H. Zhang, C. T. Feng, Z. G. Zha and Z. Y. Wang, *Angew. Chem., Int. Ed.*, 2012, 51, 8077–8081; (g) X. S. Fan, B. Li, S. H. Guo, Y. Y. Wang and X. Y. Zhang, *Chem.–Asian J.*, 2014, 9, 739–743; (h) D. Zhao, T. Wang and J. X. Li, *Chem. Commun.*, 2014, 50, 6471–6474.
- 26 R. Gundla, R. Kazemi, R. Sanam, R. Muttineni, J. A. R. P. Sarma, R. Dayam and N. Neamati, *J. Med. Chem.*, 2008, 51, 3367–3377.
- 27 S. F. Campbell, M. J. Davey, J. D. Hardstone, B. N. Lewis and M. J. Palmer, *J. Med. Chem.*, 1987, 30, 49–57.
- 28 C. E. S. Short, Y. C. Gilleece, M. J. Fisher and D. R. Churchill, *AIDS*, 2009, 23, 1287–1290.
- 29 (a) D. N. Garad, A. B. Viveki and S. B. Mhaske, *J. Org. Chem.*, 2017, 82, 6366–6372; (b) C. Milite, E. Barresi, E. Pozzo, B. Costa, M. Vivian, A. Porta, A. Messere, G. Sbardella, F. Settimo, E. Novellino, S. Coscoati, S. Castellano, S. Talian and C. Martini, *J. Med. Chem.*, 2017, 60, 7897–7909; (c) M. Hrast, K. Rozman, M. Jukic, D. Patin, S. Gobec and M. Sova, *Bioorg. Med. Chem. Lett.*, 2007, 27, 3529–3533; (d) A. Ward, L. L. Dong, J. M. Harris, K. K. Khanna, F. Al-Eje, D. P. Fairlie, A. P. Wiegman and L. G. Liu, *Bioorg. Med. Chem. Lett.*, 2007, 27, 3096–3100; (e) H. A. Abuelizz, R. E. Dib, M. Marzouk, E. H. Anouar, Y. A. Maklad, H. N. Attia and R. Al-Salahi, *Molecules*, 2017, 22, 1094–1107; (f) G. F. Smith and M. D. Altman, *Bioorg. Med. Chem. Lett.*, 2007, 27, 2721–2726.
- 30 (a) Y. Y. Peng, G. Y. S. Qiu, Q. Yang, J. J. Yuan and Z. H. Deng, *Synthesis*, 2012, 44, 1237–1246; (b) H. Lu, Q. Yang, Y. R. Zhou, Y. Q. Guo, Z. H. Deng, Q. P. Ding and Y. Y. Peng, *Org. Biomol. Chem.*, 2014, 12, 758–764; (c) M. k. Wei, W. M. Chai, R. Wang, Q. Yang, Z. H. Deng and Y. Y. Peng, *Bioorg. Med. Chem.*, 2017, 25, 1303–1308; (d) Y. Zhao, W. S. Liu, Q. Li, Q. Yang, W. B. Chai, M. J. Zeng, R. H. Li and Y. Y. Peng, *Bull. Environ. Contam. Toxicol.*, 2015, 94, 376–381.
- 31 X. Zhao, Y. R. Zhou, Q. Yang, Y. P. Xie, Q. P. Ding, Z. H. Deng, M. Zhang, J. S. Xu and Y. Y. Peng, *Synthesis*, 2013, 45, 3245–3250.
- 32 L. D. Hu, H. F. Xu, Q. Yang, Z. H. Deng, C.-Y. Yu and Y. Y. Peng, *J. Organomet. Chem.*, 2017, 843, 20–25.
- 33 (a) W. Gao, Q. P. Ding, J. J. Yuan, X. C. Mao and Y. Y. Peng, *Chin. J. Chem.*, 2017, 35, 1717–1725; (b) W. Gao, C. Gong, L. C. Xu, R. Gan and W. Y. Huang, Faming Zhuan Li Shen Qing, CN106632086, 2017; (c) W. Gao, Y. Y. Peng and Q. P. Ding, Faming Zhuan Li Shen Qing, CN106632087, 2017.

